Literature DB >> 12038606

Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders.

O A Mojiminiyi1, R Marouf, N Abdella, M Kortom, R Abdul-Razzak.   

Abstract

BACKGROUND: Recent reports have shown elevated concentrations of serum cystatin C (CC) in patients with solid tumours. The aim of our study was to investigate whether patients with proliferative haematological disorders have increased serum concentrations of CC compared with normal subjects.
METHODS: Full blood count, serum CC, beta2-microglobulin (beta2M) and serum creatinine were determined in 27 apparently healthy subjects and 35 patients with proliferative haematological disorders. Creatinine clearance was calculated using the Cockroft-Gault formula.
RESULTS: CC and beta2M showed a significant correlation with each other (r=0.96, P<0.0001). Serum beta2M (P=0.001) and the serum beta2M:CC ratio (P=0.001) were significantly higher in the patients with normal renal function than in controls, but serum CC was not significantly different (P=0.08). CC did not show a significant correlation with blood count parameters. DISCUSSION: Compared with beta2M and the beta2M:CC ratio, serum CC is not influenced by cell proliferation in haematological disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12038606     DOI: 10.1258/0004563021902017

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  9 in total

1.  Prognostic significance of serum cystatin C in multiple myeloma.

Authors:  Holger Nückel; Christian Langer; Stefan Herget-Rosenthal; Marc Wichert; Roland Assert; Hartmut Döhner; Ulrich Dührsen; Peter Liebisch
Journal:  Int J Hematol       Date:  2012-03-18       Impact factor: 2.490

2.  Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients.

Authors:  Sophie Séronie-Vivien; Stéphanie Toullec; Laurence Malard; Fabienne Thomas; Valérie Durrand; Etienne Chatelut
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Comparison of renal function markers in Kuwaiti patients with sickle cell disease.

Authors:  R Marouf; O Mojiminiyi; N Abdella; M Kortom; H Al Wazzan
Journal:  J Clin Pathol       Date:  2006-04       Impact factor: 3.411

4.  Cystatin C--a paradigm of evidence based laboratory medicine.

Authors:  Janice S C Chew; Mohammed Saleem; Christopher M Florkowski; Peter M George
Journal:  Clin Biochem Rev       Date:  2008-05

5.  Comparison of glomerular function tests in children with cancer.

Authors:  Marika H Grönroos; Timo Jahnukainen; Kerttu Irjala; Risto Härkönen; Saija Hurme; Merja Möttönen; Toivo T Salmi
Journal:  Pediatr Nephrol       Date:  2008-01-23       Impact factor: 3.714

6.  Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?

Authors:  Xue Tian; Xinxing Zhang; Min Yu; You Lu; Zhenyu Ding; Meijuan Huang; Feng Peng; Li Ren; Jin Wang; Yongsheng Wang; Yong Xu; Jiang Zhu; Lin Zhou; Xiaojuan Zhou; Min Deng; Xin Tang; Youling Gong
Journal:  Int J Clin Oncol       Date:  2017-11-04       Impact factor: 3.402

7.  Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units.

Authors:  Pierre Delanaye; Bernard Lambermont; Jean-Paul Chapelle; Jacques Gielen; Paul Gerard; Georges Rorive
Journal:  Intensive Care Med       Date:  2004-02-24       Impact factor: 17.440

8.  Evaluation of Serological Indicators and Glomerular Filtration Rate Equations in Chinese Cancer Patients.

Authors:  Yingna Tong; Xiaobin Liu; Mingxiu Guan; Meng Wang; Lufang Zhang; Dong Dong; Ruifang Niu; Fei Zhang; Yunli Zhou
Journal:  Med Sci Monit       Date:  2017-06-17

Review 9.  Cystatin C: a new renal marker and its potential use in small animal medicine.

Authors:  L Ghys; D Paepe; P Smets; H Lefebvre; J Delanghe; S Daminet
Journal:  J Vet Intern Med       Date:  2014-05-09       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.